Centre for Genomic Pathogen Surveillance, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom.
MRC Centre for Molecular Bacteriology and Infection, Imperial College London, London, United Kingdom.
PLoS Pathog. 2022 Jul 11;18(7):e1010334. doi: 10.1371/journal.ppat.1010334. eCollection 2022 Jul.
Mutations in outer membrane porins act in synergy with carbapenemase enzymes to increase carbapenem resistance in the important nosocomial pathogen, Klebsiella pneumoniae (KP). A key example is a di-amino acid insertion, Glycine-Aspartate (GD), in the extracellular loop 3 (L3) region of OmpK36 which constricts the pore and restricts entry of carbapenems into the bacterial cell. Here we combined genomic and experimental approaches to characterise the diversity, spread and impact of different L3 insertion types in OmpK36. We identified L3 insertions in 3588 (24.1%) of 14,888 KP genomes with an intact ompK36 gene from a global collection. GD insertions were most common, with a high concentration in the ST258/512 clone that has spread widely in Europe and the Americas. Aspartate (D) and Threonine-Aspartate (TD) insertions were prevalent in genomes from Asia, due in part to acquisitions by KP sequence types ST16 and ST231 and subsequent clonal expansions. By solving the crystal structures of novel OmpK36 variants, we found that the TD insertion causes a pore constriction of 41%, significantly greater than that achieved by GD (10%) or D (8%), resulting in the highest levels of resistance to selected antibiotics. We show that in the absence of antibiotics KP mutants harbouring these L3 insertions exhibit both an in vitro and in vivo competitive disadvantage relative to the isogenic parental strain expressing wild type OmpK36. We propose that this explains the reversion of GD and TD insertions observed at low frequency among KP genomes. Finally, we demonstrate that strains expressing L3 insertions remain susceptible to drugs targeting carbapenemase-producing KP, including novel beta lactam-beta lactamase inhibitor combinations. This study provides a contemporary global view of OmpK36-mediated resistance mechanisms in KP, integrating surveillance and experimental data to guide treatment and drug development strategies.
外膜孔蛋白突变与碳青霉烯酶协同作用,增加重要医院病原体肺炎克雷伯菌(KP)对碳青霉烯类药物的耐药性。一个重要的例子是,OmpK36 的细胞外环 3(L3)区域中的二氨基酸插入甘氨酸-天冬氨酸(GD),使孔变窄并限制碳青霉烯类药物进入细菌细胞。在这里,我们结合基因组和实验方法来描述 OmpK36 中不同 L3 插入类型的多样性、传播和影响。我们从全球收集的具有完整 ompK36 基因的 14888 个 KP 基因组中鉴定出 3588 个(24.1%)L3 插入。GD 插入最为常见,在广泛传播于欧洲和美洲的 ST258/512 克隆中高度集中。天冬氨酸(D)和苏氨酸-天冬氨酸(TD)插入在亚洲的基因组中很普遍,部分原因是 KP 序列型 ST16 和 ST231 的获得以及随后的克隆扩张。通过解决新型 OmpK36 变体的晶体结构,我们发现 TD 插入导致孔缩窄 41%,明显大于 GD(10%)或 D(8%),导致对选定抗生素的耐药性最高。我们表明,在没有抗生素的情况下,携带这些 L3 插入的 KP 突变体相对于表达野生型 OmpK36 的同基因亲本菌株,在体外和体内都表现出竞争劣势。我们提出,这解释了在 KP 基因组中观察到的 GD 和 TD 插入的低频回复。最后,我们证明表达 L3 插入的菌株仍然对针对产碳青霉烯酶 KP 的药物敏感,包括新型β-内酰胺-β-内酰胺酶抑制剂组合。本研究提供了 KP 中 OmpK36 介导的耐药机制的当代全球视图,整合了监测和实验数据,以指导治疗和药物开发策略。